DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Generic Name: dalfampridine

Summary for Generic Name: dalfampridine

Tradenames:1
Patents:5
Applicants:1
NDAs:1
Drug Master File Entries: see list7
Suppliers: see list1

Clinical Trials for: dalfampridine

Ampyra for Optic Neuritis in MS
Status: Completed Condition: Multiple Sclerosis; Optic Neuritis

A New Medicine to Treat Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Active, not recruiting Condition: Non Arteritic Ischemic Optic Neuropathy

An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS)
Status: Completed Condition: Multiple Sclerosis

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis
Status: Completed Condition: Multiple Sclerosis

Combination Therapy With Dalfampridine and Locomotor Training for Chronic, Motor Incomplete Spinal Cord Injury
Status: Recruiting Condition: Spinal Cord Injury

Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy
Status: Completed Condition: Cerebral Palsy (CP)

A Pharmacokinetics (PK) and Safety Study of Oral Fampridine-PR 10 mg in Chinese, Japanese, and Caucasian Adult Healthy Volunteers
Status: Completed Condition: Healthy

Pharmacokinetics (PK) of Dalfampridine-ER 7.5 mg BID in Healthy Volunteers and Subjects With Mild or Moderate Renal Impairment
Status: Completed Condition: Renal Insufficiency

Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis
Status: Terminated Condition: Transverse Myelitis

Dalfampridine and Gait in Spinocerebellar Ataxias
Status: Completed Condition: Spinocerebellar Ataxias Type 1; Spinocerebellar Ataxias Type 2; Spinocerebellar Ataxias Type 3; Spinocerebellar Ataxias Type 6

Courtesy of ClinicalTrials.org
See more clinical trials for this drug

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Acorda
AMPYRA
dalfampridine
TABLET, EXTENDED RELEASE;ORAL022250Jan 22, 2010RXYes5,540,938<disabled>IMPROVEMENT OF WALKING IN PATIENTS WITH MULTIPLE SCLEROSIS (MS)
Acorda
AMPYRA
dalfampridine
TABLET, EXTENDED RELEASE;ORAL022250Jan 22, 2010RXYes8,007,826<disabled>IMPROVEMENT OF WALKING IN PATIENTS WITH MULTIPLE SCLEROSIS (MS)
Acorda
AMPYRA
dalfampridine
TABLET, EXTENDED RELEASE;ORAL022250Jan 22, 2010RXYes8,354,437<disabled>IMPROVEMENT OF WALKING IN PATIENTS WITH MULTIPLE SCLEROSIS (MS)
Acorda
AMPYRA
dalfampridine
TABLET, EXTENDED RELEASE;ORAL022250Jan 22, 2010RXYes8,440,703<disabled>IMPROVEMENT OF WALKING IN PATIENTS WITH MULTIPLE SCLEROSIS (MS)
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc